SCHEMBL177140

SCHEMBL177140

O=C(O)c1ccc(Br)c(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.65
MAPT P10636 5/20 0.55
SRD5A2 P31213 2/20 0.52
TTR P02766 2/20 0.50
ALDH1A1 P00352 3/20 0.48
ALOX15 P16050 2/20 0.48
HTT P42858 3/20 0.47
MEN1 O00255 3/20 0.47
LMNA P02545 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.46
PKM P14618 1/20 0.45
GAA P10253 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530501 0.84 RXRA (0.56) TSHRMAPTSRD5A2ALOX15LMNA
SCHEMBL38657986 0.83 MAPT (0.51) TSHRMAPTSRD5A2TTRALDH1A1
SCHEMBL30375607 0.83 TSHR (0.65) TSHRMAPTSRD5A2TTRALDH1A1
SCHEMBL112432 0.83 TSHR (0.65) TSHRMAPTSRD5A2TTRALDH1A1
SCHEMBL320780 0.83 MAPT (0.55) TSHRMAPTSRD5A2ALDH1A1ALOX15
SCHEMBL1439135 0.81 MAPT (0.53) TSHRMAPTALDH1A1ALOX15HTT
SCHEMBL6139728 0.81 MAPT (0.64) TSHRMAPTALDH1A1ALOX15HTT
SCHEMBL29996684 0.81 MAPT (0.64) TSHRMAPTALDH1A1ALOX15HTT
SCHEMBL1129174 0.80 L3MBTL1 (0.55) MAPTSRD5A2ALDH1A1ALOX15HTT
SCHEMBL31620838 0.80 MAPT (0.49) TSHRMAPTSRD5A2TTRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-110759831-B Method for preparing halofuginone intermediate 2-amino-4-bromo-5-chlorobenzoic acid 浙江金伯士药业有限公司 2022-09-27 CN claimed
CN-122079899-A Application of pharmaceutical composition in preparation of medicines for preventing or treating diseases related to Sirttail 7 protein 2026-05-26 CN disclosed
EP-4735422-A1 SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS Sanofi (FR) 2026-05-06 EP disclosed
US-20260108521-A1 GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME BIOFRONT LTD (KY) 2026-04-23 US disclosed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 US disclosed
EP-4695271-A2 A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA Merck Sharp & Dohme LLC (US) 2026-02-18 EP disclosed
US-12479817-B2 Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2025-11-25 US disclosed
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-10-07 US disclosed
US-12421228-B2 Naphthyridine derivatives as PRC2 inhibitors Mirati Therapeutics, Inc. (US) 2025-09-23 US disclosed
US-20250282787-A1 SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS Mirati Therapeutics, Inc. 2025-09-11 US disclosed
WO-2007102767-A1 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 2007-09-13 WO disclosed
CN-1826310-A Novel aminobenzophenone compounds LEO PHARMA AS (DK) 2006-08-30 CN disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP disclosed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO disclosed
US-5804532-A REACTING A BENZOYL ISOXAZOLE WITH A BASE RHONE-POULENC AGRICULTURE LIMITED (GB) 1998-09-08 US disclosed
US-5223539-A Antagonist of platelet activating factor G. D. SEARLE & CO. (US) 1993-06-29 US disclosed
WO-1993010077-A1 N,N-DI-ALKYL(PHENOXY)BENZAMIDE DERIVATIVES G.D. SEARLE & CO. (US) 1993-05-27 WO disclosed
EP-0279698-A2 Pesticidal compounds THE WELLCOME FOUNDATION LIMITED (GB) 1988-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479817-B2 Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof XDH, RXFP3, NPY2R TSHR 1339/4885MAPT 99/4885SRD5A2 451/4885
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 TSHR 4539/4885MAPT 2456/4885SRD5A2 1643/4885
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 INMT, CARM1, KDM1B TSHR 3555/4885MAPT 3740/4885SRD5A2 2866/4885
US-20260108521-A1 GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME GHSR, GSPT1, GLRA1 TSHR 140/4885MAPT 910/4885SRD5A2 190/4885
US-20250282787-A1 SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS EZH2, BMI1, SUZ12 TSHR 4715/4885MAPT 3874/4885SRD5A2 1923/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 TSHR 246/4885MAPT 4259/4885SRD5A2 51/4885
US-12421228-B2 Naphthyridine derivatives as PRC2 inhibitors BMI1, EZH2, SUZ12 TSHR 4567/4885MAPT 3360/4885SRD5A2 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.